Your browser version is outdated. We recommend that you update your browser to the latest version.

DeNovX is ...

new IP6

an innovative pharmaceutical technology company that provides platform products and services that accelerate pharmaceutical development while creating new intellectual property (IP) for commercially relevant drugs.

 

Over 90% of active pharmaceutical ingredients (APIs) are crystalline solids, and our platform technologies reduce the risks associated with controlling the size, shape, and structure of these high value materials while creating new IP to enhance competitive advantage and to extend product life cycles.

 

Think Forward - to rational crystal screening and solid form controls.   

   

Challenges

 

 

Control of the size, shape, and structure of crystalline active pharmaceuticals ingredients remains a challenge in R&D and production.

Screening Solutions

 

 

Screening with crystallization platforms based on self assembled monolayers (SAMs) is fast and mass efficient.

Manufacturing Services

 

 

Work with us to explore continuous crystallization processes that replace costly batch methods and give better control of crystal size distribution.